Synapse - Karen Autio

Results (120)

Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Meeting Abstract

Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Oligometastatic squamous cell transformation from metastatic prostate adenocarcinoma treated with systemic and focal therapy: A case report

Journal Article

Autio, K.; McBride, S.
Journal of Immunotherapy and Precision Oncology (2022)

Fulltext@MSK | Save

Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality

Journal Article

Keegan, N. M.; Vasselman, S. E.; Barnett, E. S.; Nweji, B.; Carbone, E. A.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
Prostate (2022)

Fulltext@MSK | Save

Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality

Meeting Abstract

Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors

Journal Article

Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Autio, K. A.; Higano, C. S.; Nordquist, L. T.; Appleman, L. J.; Zhang, T.; Zhu, X.; Babiker, H. M.; Vogelzang, N. J.; Prasad, S.; Schweizer, M. T.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy

Journal Article

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
European Urology Open Science (2021)

Fulltext@MSK | Save

CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study

Journal Article

Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
Journal for ImmunoTherapy of Cancer (2021)

Fulltext@MSK | Save

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): A first-in-human, dose-finding study